# Stratificare Pte.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stratificare-pte

- Industry: Medical Devices & Equipment
- Headquarters: Singapore, Singapore
- Website: www.stratificare.com
- Total disclosed funding: $0.7M
- Latest round: Seed (Oct 8, 2021)
- Investors on record: 2

## About

Based in Singapore, and founded in 2015 by CEO and co-founder Anthony Chua, StratifiCare Pte. Ltd., a.k.a. StratifiCare operates as a developer of IVD (In-Vitro Diagnostics) array tests and devices for assisting doctors in diagnosing severe disease complications (such as internal bleeding) and the hospitalization needs of dengue patients. In October 2021, Stratificare Pte. Ltd. raised SGD 1 million in seed funding from ADB Ventures and Sprout, with the participation of individual investors.

The company provides StratifiDen, a dengue prediction test to determine the risk of severe dengue development in patients. StratifiCare also offers StratifiREY, a diagnostic test to predict if a patient will respond to Y90 RE, enabling clinicians to make more informed decisions on whether the patient should proceed with Y90 RE or alternative treatments. The firm’s solutions enable doctors as well as clinicians to minimize hospital readmissions, reduce the usage of ineffective treatments, and enhance patient outcomes.

## Funding rounds

- Seed, Oct 8, 2021, $0.7M — ADB Ventures, Sprout

## Investors

- ADB Ventures (https://capitalatlas.ai/funds/adb-ventures) — Seed
- Sprout (https://capitalatlas.ai/funds/sprout) — Seed